CaMKII and MEK1/2 inhibition time-dependently modify inflammatory signaling in rat cerebral arteries during organ culture by Roya Waldsee et al.
JOURNAL OF 
NEUROINFLAMMATION
Waldsee et al. Journal of Neuroinflammation 2014, 11:90
http://www.jneuroinflammation.com/content/11/1/90RESEARCH Open AccessCaMKII and MEK1/2 inhibition time-dependently
modify inflammatory signaling in rat cerebral
arteries during organ culture
Roya Waldsee1, Sajedeh Eftekhari1, Hilda Ahnstedt1, Leif E Johnson2 and Lars Edvinsson1*Abstract
Background: Cerebral ischemia induces transcriptional upregulation of inflammatory genes in the brain
parenchyma and in cerebral arteries, thereby contributing to the infarct development. The present study was
designed to evaluate the involvement of calcium-calmodulin-dependent protein kinase (CaMKII) II and extracellular
signal-regulated kinase1/2 (ERK1/2) on inflammatory mediators in rat cerebral arteries using organ culture as a
method for inducing ischemic-like vascular wall changes.
Methods: Rat basilar arteries were cultured in serum-free medium for 0, 3, 6 or 24 hours in the presence or absence
of the CaMKII inhibitor KN93 or the MEK1/2 inhibitor U0126. Protein expression of activated CaMKII, ERK1/2, and
inflammatory-associated protein kinases and mediators were examined with western blot and immunohistochemistry.
Caspase-3 mRNA levels in basilar arteries were studied with real-time PCR.
Results: Western blot evaluation showed that organ culture induced a significant increase in phosphorylated ERK1/2 at
3, 6 and 24 hours, while CaMKII was found to be already activated in fresh non-incubated arteries and to decrease with
incubation time. The addition of U0126 or KN93 decreased levels of phosphorylated c-Jun N-terminal kinase and p-p38,
as evaluated by immunohistochemistry. KN93 affected the increase in caspase-3 mRNA expression only when given at
the start of incubation, while U0126 had an inhibitory effect when given up to six hours later. Tumor necrosis factor
receptor 1 was elevated after organ culture. This inflammatory marker was reduced by both of the two different protein
kinase inhibitors.
Conclusions: The novel findings of the present study are that the cross-talk between the two protein kinases and the
inhibition of CaMKII or MEK1/2 in a time-dependent manner attenuates inflammatory-associated protein kinases and
mediators, suggesting that they play a role in cerebrovascular inflammation.
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Cerebral ischemia is well-known to be associated with
inflammation [1], and its inhibition may result in re-
duced infarct volume [2,3]. Experimental middle cerebral
artery occlusion (MCAO) and subarachnoid hemorrhage
(SAH) have been shown to be associated with inflamma-
tion in the walls of cerebral arteries and in the microvas-
culature [4-7]. We have developed a method of isolated
cerebral artery culture which simulates some aspects of* Correspondence: Lars.edvinsson@med.lu.se
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unless otherwise stated.cerebrovascular inflammation [8,9]. A multitude of stimuli
have been identified that induce inflammation and apop-
tosis in vascular smooth muscle cells (VSMCs) including
nitric oxide donors [10], serum starvation [11], tumor
necrosis factor alpha (TNF-α), and interleukin-1 (IL-1)
[12]. Organ culture in serum-free medium results in in-
flammation and apoptosis in isolated vessel segments
via activation of different intracellular signals, such as
induction of caspase cascades or upregulation of Fas
ligand expression [13].
The mitogen-activated protein kinases (MAPK) are a
group of serine/threonine kinases that play an import-
ant role in intracellular signaling [14]. There are threel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Experimental design. Rat basilar arteries were incubated
according to (A) time study and (B) treatment study. Inhibitors or
vehicle was administered at 0 hours (i) or at 6 hours (ii). Arrows
indicate end points where arteries were collected for further studies.
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signal-regulated kinase1/2 (MEK/ERK1/2), p38, and c-
Jun N-terminal kinase (JNK). Cerebral ischemia and organ
culture induce early activation of ERK1/2 and somewhat
delay activation of p38 and JNK, thus demonstrating dif-
ferent time frames of activity after cerebral ischemia
[15,16]. This in turn activates transcription factor nuclear
factor kappa B (NF-κB) and c-Jun, and the subsequent ex-
pression of inflammatory genes in cerebral arteries [7,17].
Calcium/calmodulin-dependent protein kinase II
(CaMKII) is a multifunctional serine/threonine kinase
that affects different biological processes including gene
expression, cell-cycle control, and hormone production
[18]. In addition, CaMKII involvement has been shown
in neuronal apoptosis [19]. Previous organ culture studies
have demonstrated activation of MAPK kinases (MEK/
ERK1/2) in middle cerebral arteries (MCAs) [20,21] and
CaMKII in basilar arteries [22] in parallel to endothelin
receptor B (ETB) receptor upregulation. These studies
revealed a time-dependent effect of MEK/ERK1/2 and
CaMKII inhibitors on ETB receptor upregulation at
protein and functional levels.
The present study analyzes the time course of stress
signaling in response to organ culture by characterizing
the phosphorylation of CaMKII, ERK1/2, JNK, and p38,
and the levels of caspase-3, an executor of apoptosis. In
addition, we studied TNF-α-receptor 1 (TNFR1) since
TNF-α initiates inflammation in many cell types [23,24]
via its receptor and has a role in cerebrovascular inflam-
mation [5]. We hypothesize that organ culture-induced
inflammation may share some features with the in vivo
situation following stroke, and therefore evaluated U0126
and KN93, specific inhibitors of MEK1/2 and of CaMKII,
respectively, which have demonstrated beneficial effects
in vivo [8].
Methods
Male Sprague-Dawley rats (Scanbur, Stockholm, Sweden)
weighing 250 - 300 g were housed under controlled
conditions and used for the study. The Animal Ethics
Committee, Lund, Sweden, approved the experiments
(M217-03, M161-07).
Tissue preparation
The animals (total number used, n = 113) were sacrificed
by CO2 followed by decapitation. The basilar arteries were
isolated and placed in a cold bicarbonate buffer solution
with the following composition (in mM): NaCl 119,
NaHCO315, KCl 4.6, NaH2PO4 1.2, MgCl2 1.2, CaCl21.2,
and glucose5.5. The arteries were incubated in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco, Life Technolo-
gies Europe BV, Stockholm, Sweden) supplemented with
penicillin (100 U/mL), streptomycin (100 μg/ml), and
amphotericin B (0.25 μg/ml) at 37°C in humidified 5%CO2 and air. The experimental design is depicted in
Figure 1. For the time study, vessels were incubated in
DMEM for 0, 3, 6 or 24 hours where 0 hours was consid-
ered as the control (Figure 1A). The CaMKII inhibitor
KN93 (10−5 M) or the MEK1/2 inhibitor U0126 (10−5 M)
were added at 0 or 6 hours after initiating the incubation
(Figure 1B). Artery segments incubated with vehicle (equal
volume of dimethyl sulfoxide (DMSO)) were used as the
control in the treatment study.
Tissue lysis and protein content determination
After incubation, the arteries were collected (total number
of rats used n = 48) and homogenized in denaturing cell
extraction buffer (Life Technologies Europe BV) supple-
mented with protease and phosphatase inhibitors (Sigma,
St Louis, Missouri, United States). After 20 minutes of
incubation on ice, homogenates were centrifuged at
13000 g for 10 minutes at 4°C and the supernatant was
collected. Total protein concentration was determined
using a Bio-Rad protein assay dye (Hercules, California,
United States) and measurement of the absorbance at
595 nm on an Infinite M200 micro plate reader (Tecan,
Männedorf, Switzerland) was obtained.
Western blot analysis
Lysates were dissolved in a Laemmli sample buffer (Bio-
Rad) supplemented with 2-mercaptoethanol (Bio-Rad)
and boiled for 4 minutes at 95°C. Equal amounts of pro-
teins (40 to 50 μg/lane) were loaded on a 4 to 15% linear
gradient Trizma hydrochloride (Tris- HCl) gel (Bio-Rad)
and separated by SDS-polyacrylamide gel electrophoresis.
Molecular weight markers (Fisher Scientific, Bio-Rad)
were loaded onto each gel for protein band identifica-
tion. After separation, proteins were transferred onto a
nitrocellulose (Bio-Rad) or polyvinylidene fluoride (Life
Technologies) membrane. Subsequently, the membrane
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Buffered Saline (T-TBS, pH 7.6) for 1 hour at room
temperature, followed by three 5 minute washes with
T-TBS. For detection of phosphorylated CaMKII, 1%
non-fat milk and 1% bovine serum albumin (BSA) in
T-TBS supplemented with protease and phosphatase
inhibitors (Sigma) was used as a blocking solution. Mem-
branes were then incubated with one of the following
primary antibodies: mouse monoclonal anti-CaMKII
phospho-specific (1:1000; Santa Cruz Biotechnology,
Santa Cruz, California, United States), rabbit monoclo-
nal anti-CaMKII (1:20 000; Abcam, Cambridge, United
Kingdom), rabbit polyclonal anti-ERK1/2 phospho-specific
(1:1000; Cell Signaling Technology, Beverly, Massachusetts,
United States), mouse anti-phosphorylated-JNK (1:750,
Santa Cruz Biotechnology), mouse anti-alpha tubulin
(1:60000, Abcam) and mouse monoclonal anti-ERK1/2
(1:2000; Cell Signaling) overnight at 4°C, followed by
three 5 minute washes with T-TBS. Subsequently, the
membranes were incubated with the appropriate horse-
radish peroxidase conjugated secondary antibodies for
1 hour at room temperature, followed by four 5 minute
washes with T-TBS and one 5 minute wash with TBS.
The membranes were developed using a Supersignal
West Dura kit (Pierce, Rockford, Illinois, United States)
or a Western chemiluminescent horseradish peroxidase
(HRP) solution (Millipore Billerica, MA, USA) and visu-
alized using a luminescence image analyzer. For reprob-
ing, blots were stripped by incubating the membranes
for 45 minutes in stripping buffer (0.0625 M Tris-HCl
containing 2% SDS and 0.007% 2-mercaptoethanol,
pH 6.8), blocked again for 1 hour and treated as de-
scribed above with new primary antibodies. Protein
band densities were quantified using the Image J soft-
ware (National Institutes of Health, Bethesda, Maryland,
USA) or Image Lab 5.1 software (Bio Rad). The optical
density values are presented as absolute ratios of the
phosphorylated levels of CaMKII and ERK1/2 to the
total levels, and for phosphorylated JNK the optical
density values show the inhibitor-treated samples as a
percent of the control value.
Molecular biology
Basilar artery segments (total number of rats used n = 40)
were incubated in DMEM for 0, 3, 6, or 24 hours for
time-dependent evaluation of caspase-3 during organ
culture. To evaluate the role of CaMKII or MEK/ERK1/2
in caspase-3 activation, basilar artery segments were
cultured for 24 hours in the presence or absence of
KN93 (10−5 M) or U0126 (10−5 M) added at 0 or 6 hours
after initiating incubation (Figure 1B). The concentra-
tions have been evaluated previously [21,22]. The vessel
segments were immediately snap-frozen and stored
at -80°C until use. Total cellular RNA was extractedusing a FastRNA Pro Green kit (Qbiogene, Illkirsh,
France) for 60 seconds in the FastPrep FP120 instrument
(Qbiogene) following the manufacturer’s instructions. First
strand cDNA was synthesized from 200 ng total RNA in a
40 μl reaction volume using random hexamers as primers.
Quantitative real-time PCR (qPCR) was performed in a
GeneAmp 5700 Sequence Detection System using the
GeneAmp SYBR® Green kit (Perkin-Elmer, Applied Bio-
systems, Foster City, California, United States) with the
cDNA synthesized above as the template in a 28 μl reac-
tion volume. A sample without the template served as the
control. Specific primers were designed as caspase-3; 5’-
AATTCAAGGGACGGGTCATG-3’ as the forward and
5’-GCTTGTGCGCGTACAGTTTC-3’ as the reverse [25].
The housekeeping gene was elongation factor-1 (EF-1)
with 5’-GCAAGCCCATGTGTGTTGAA-3’as the forward
and 5’-TGATGACACCCACAGCAACTG-3’ as the reverse.
In previous studies, we examined and compared EF-1,
β-actin, and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as the housekeeping genes and verified that
EF-1 is stable during the organ culture procedure [7].
Immunohistochemistry
Basilar artery segments (total number of rats n = 25)
were cultured for 24 hours with KN93 or U0126 admin-
istered at 0 or 6 hours after initiating incubation. Vessels
incubated for 24 hours without inhibitor served as the
controls. Subsequently, the basilar artery segments were
embedded in Tissue TEK (Histolab, Västra Frölunda,
Sweden), frozen at -80°C, and cryosectioned (10 μm,
Cryo-star HM 560 M Thermo Scientific, Microm,
Waltham, MA USA). The sections were fixed for
10 minutes in ice-cold acetone, followed by rehydration in
phosphate buffered-saline (PBS, pH 7.2) containing 0.25%
Triton X-100 (PBST) for three times at 5 minutes each,
and incubated with blocking solution containing PBS and
5% normal donkey serum for 1 hour. After blocking, the
sections were incubated overnight at 4°C with one of
the following primary antibodies: rabbit anti-CaMKII
(1:100; Abcam, Cambridge, United Kingdom), mouse
anti-phospho-JNK (1:100, Santa Cruz Biotechnology),
rabbit anti-phospho-p38 (1:50, Cell Signaling Technology)
or rabbit anti TNF-α receptor I (1:1500, Abcam). The
primary antibodies were diluted in PBST, containing 1%
BSA and 3% normal donkey serum. After incubation
with the primary antibodies, sections were washed three
times (15 minutes each wash) in PBST and incubated
with secondary antibody Cy™2-conjugated donkey anti-
rabbit (1:200, Jackson ImmunoResearch, West Grove,
Pennsylvania, United States) or donkey Texas-Red anti-
mouse (1:100, Jackson ImmunoResearch) diluted in
PBST and 1% BSA, for 1 hour at room temperature. The
sections were subsequently washed three times in PBST
for 15 minutes each wash, thereafter mounted with
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antibodies served as negative controls for all antibodies.
Sections were examined and images were obtained using
an epifluorescence microscope (Olympus Microscope
BX 60, Tokyo, Japan) at the appropriate wavelengths.
Fluorescence intensity measurements were made in the
media layer of the vessels with the use of the software
program Image J (National Institutes of Health, Bethesda,
Maryland, USA). For measurement analysis, there were
five rats per group and between four and six sections from
each rat were evaluated. The fluorescence intensity was
measured in four areas in each section and the mean value
of the intensity per measured area was used. The immu-
noreactivity of the individual receptors was visualized
with the same microscope settings during the same day
for all groups.
Statistics
Results are given as mean ± SEM, and n refers to the
number of rats. There were n = 3 samples per group inFigure 2 Basilar artery segments were incubated for 0, 3, 6, or 24 hou
western blot and detected by immunofluorescence. (B) ERK1/2 was measured
the total levels of the kinases. Significant differences were obtained between
mean ± SEM, n = 5. *P <0.05. Extracellular signal regulated kinase 1/2 (ERK1/2the western blot experiments (the basilar arteries from
three rats were pooled to constitute on sample). In the
immunohistochemistry experiments there were n = 5
rats in each group, while there were between four and six
rats in the real-time PCR experiments. Kruskal-Wallis
nonparametric test with Dunn’s post-hoc test was used
for all statistical analyses. The level of significance was
set to P <0.05.
Results
Activation of ERK1/2 and CaMKII during organ culture
Time-dependent phosphorylation of ERK1/2 and CaMKII
was evaluated by western blot. High levels of activated
CaMKII were found in freshly isolated and non-incubated
arteries (Figure 2A) in accordance with an earlier study
[22]. The p-CaMKII expression decreased with incuba-
tion time to a significant difference at 6 and 24 hours
(P <0.05). Immunofluorescence results showed similar
results, CAMKII immunoreactivity was high at 0 hours
and decreased during the time of organ culture (Figure 2A).rs. Phosphorylated and total level of CaMKII (A) were measured by
by western blot. Phosphorylated CaMKII and ERK1/2 were compared to
fresh (0 hours) and incubated arteries for western blot. Data are shown as
), calcium calmodulin-dependent protein kinase II (CAMKII).
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after initiating incubation and remained elevated for up
to 24 hours compared to 0 hours (P <0.05, Figure 2B).
These results show apparent differences in p-ERK1/2
and p-CaMKII levels at 0 and 6 hours of incubation.
Therefore, MEK1/2 or CaMKII inhibitors were added at
these time points to investigate the time-dependent ef-
fect of these inhibitors on inflammatory mediators.
Caspase-3 during organ culture
Caspase-3 mRNA level was evaluated at 0, 3, 6 and
24 hours after organ culture by real-time PCR [25]. The
mRNA level of caspase-3 increased in a time-dependent
manner and was significantly elevated at 6 and 24 hours
(P <0.05 and P <0.01, Figure 3A). Furthermore, the effects
of the inhibitors U0126 and KN93 on caspase-3 mRNA
levels were evaluated. Figure 3B demonstrates a significant
(P <0.01) reduction in caspase-3 mRNA levels in arteries
incubated with KN93 only if it was added at the start of
incubation (0 hours). KN93 caused a significant reduction
of caspase-3 mRNA levels if it was added at 0 hours, but
did not have a significant effect when given at 6 hours
after initiation of incubation (P <0.05). U0126 on the other
hand, added at 0 or 6 hours after initiating incubation, sig-
nificantly decreased caspase-3 mRNA levels (P <0.01 and
P <0.001, respectively). These results show that U0126 has
an inhibitory effect when added at either 0 or 6 hours after
initiating incubation.Figure 3 Relative caspase-3 mRNA levels in incubated arteries. (A) eva
serum-free DMEM (0 hours was used as control) and (B) in arteries incubat
MEK1/2 inhibitor (U0126, 10−5 M) added at 0 or 6 hours after initiating incu
Data are presented as mean ± SEM relative to (elongation factor-1) EF-1, n
difference between 0 and 6 hours in arteries incubated with KN93. Dulbecc
protein kinase II (CAMKII).Effects of KN93 and U0126 on p-JNK and p-p38
Protein analysis by immunohistochemistry revealed that
KN93 added at 0 or 6 hours after initiating incubation
significantly decreased the level of phosphorylated c-Jun
N-terminal kinase (p-JNK) compared to the control
(24-hours incubation in the presence of vehicle) (P <0.05,
Figure 4). Western blot analysis showed that p-JNK de-
creased by 16% in KN93-treated samples (0 hours) as
compared to untreated controls, but this difference was
not statistically significant (data not shown). Phosphor-
ylated p38 was significantly reduced by KN93 given at
0 hours (P <0.05) but not at 6 hours (P >0.05, Figure 4).
Thus, KN93 had a differential inhibitory effect of p-JNK
and p-p38.
MEK1/2 inhibition had similar effects on p-JNK when
added at 0 hours (P <0.01) or at 6 hours (P <0.05) after
start of incubation (Figure 5). Western blot analysis
showed that p-JNK decreased by 23% in KN93-treated
samples (0 hours) as compared to untreated controls,
but this difference was not statistically significant (data
not shown). U0126 also decreased p-p38 levels at both
time points (at 0 hours P <0.001 and at 6 hours P <0.01,
Figure 5). There was no significant difference in the
inhibitory effect of U0126 when given at 0 or 6 hours.
The results show that both inhibitors affect the activa-
tion of p38 and JNK at 24 hours of incubation, but only
U0126 had an inhibitory effect on p-p38 when given at
6 hours after initiating incubation.luated in arteries incubated for 0 (fresh), 3, 6 or 24 hours in
ed for 24 hours with or without CaMKII inhibitor (KN93, 10−5 M) or
bation (24-hour-incubated arteries with vehicle were used as control).
= 4–6. *P <0.05 **P <0.01, ***P <0.001. ^P <0.05 represents significant
o’s modified eagle’s medium (DMEM), calcium calmodulin-dependent
Figure 4 Effect of the CAMKII inhibitor on p-p38 and p-JNK levels in incubated arteries (A) Fluorescence intensity and (B) expression of
p-p38 and p-JNK in the vascular smooth muscle cell layer of cerebral arteries incubated for 24 hours in presence or absence of the CaMKII
inhibitor KN93 added at 0 or 6 hours after initiating incubation. (A, D) Arteries incubated in the presence of vehicle for 24 hours were used as the
control and treatments compared to this level of expression (set as 100%). (B, E) KN93 added at 0 hours, (C, F) KN93 added at 6 hours. Data are
presented as mean ± SEM relative to control, n = 5, *P <0.05. ^^P <0.01 represents significant difference in p-p38 protein level between 0 and 6 hours.
Negative controls (omission of primary antibody) for Cy2 -conjugated donkey anti-rabbit and Texas-Red-conjugated donkey anti-mouse. Calcium
calmodulin-dependent protein kinase II (CAMKII), phosphorylated c-Jun N-terminal kinase (p-JNK).
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We also investigated whether inhibition of MEK1/2 or
CaMKII had any effect on expression of the putative ini-
tiator of inflammatory signaling, the TNF-α receptor.
We therefore studied TNFR1 protein expression that is
one of the starting signals in inflammatory activity [23,24].
Previous work has demonstrated that organ culture elicitsFigure 5 Effect of the MEK1/2 inhibitor on p-p38 and p-JNK levels in
of p-p38 and p-JNK in the vascular smooth muscle cell layer of cereb
MEK1/2 inhibitor U0126 added at 0 or 6 hours after initiating incubat
used as control. (B, E) U0126 added at 0 hours, (C, F) U0126 added at 6 hou
*P <0.05, **P <0.01, ***P <0.001. Calcium calmodulin-dependent protein kinan enhanced expression of TNF-α and TNFR1 both
after organ culture and during in vivo stroke [5]. The
present results revealed that incubation with U0126 or
KN93 lowered the protein level of TNFR1 at 24 hours of
incubation compared to control (set to 100%) (Figure 6).
KN93 had a significant effect (P <0.05) only when added
at 0 hours of incubation, while U0126 significantlyincubated arteries (A) Fluorescence intensity and (B) expression
ral arteries incubated for 24 hours in presence or absence of the
ion. (A, D) Arteries incubated for 24 hours in presence of vehicle were
rs. Data are presented as mean ± SEM relative to control. n = 5
ase II (CAMKII), phosphorylated c-Jun N-terminal kinase (p-JNK).
Figure 6 Effect of the MEK1/2 inhibitor or the CAMKII inhibitor on TNFR1 levels in incubated arteries (A) Fluorescence intensity and (B)
expression of TNFR1 in the vascular smooth muscle cell layer of cerebral arteries incubated for 24 hours in presence or absence of the
MEK1/2 inhibitor U0126 or the CAMKII inhibitor KN93, added at 0 or 6 hours after initiating incubation. Data are presented as mean ±
SEM relative to 24 hours incubation in presence of vehicle (control). n = 5. *P <0.05, **P <0.01. ^^P <0.01 represents significant difference in
TNFR1 protein level between 0 and 6 hours in arteries treated with U0126. Calcium calmodulin-dependent protein kinase II (CAMKII), tumor
necrosis factor receptor 1 (TNFR1).
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6 hours of incubation (P <0.01). The results demon-
strate time-dependent differences in the inhibitory effect
of U0126 and KN93.
Discussion
CaMKII and MEK1/2 have been shown to be involved in
cerebrovascular receptor upregulation after cerebral
ischemia [8,22]. The exact mechanisms involved in
vascular inflammation are, however, poorly understood
[1]. Earlier studies have revealed that cerebral ischemia
and organ culture in particular activates intracellular
signaling kinases including CaMKII [22], MEK/ERK1/2,
JNK, p38, inflammatory cytokines, and metalloproteinases
in cerebral arteries [15,17,26]. Activation of MEK/ERK1/2
occurs in parallel with ETB receptor upregulation after
organ culture [21,22], in SAH [27] and MCAO [28]. In
contrast, CaMKII shows a lower degree of activation
(p-CaMKII expression) and KN93 has an effect only
when the inhibitor is given early or in conjunction with
the cerebral ischemia [29]. The inhibition of CaMKII
and MEK1/2 results in attenuated ETB receptor upreg-
ulation and improved neurological outcome after SAH
[29]. The present study was designed to evaluate the
time-dependent effects of CaMKII and MEK1/2 inhibitors
on signaling kinases and proteins involved in cerebrovas-
cular inflammatory responses using an in vitro approach
that mimics several of the ischemic-like vascular wall
changes [5,9].
The present results suggest an important role and cross-
talk between CaMKII and ERK1/2 kinases in the inflam-
matory and apoptotic activity in the VSMCs. The novel
finding of this study is that administration of a CaMKII
inhibitor at 0 hours or a MEK1/2 inhibitor as late as
6 hours after initiating incubation has pronouncedeffects on inflammatory signals in the cerebral vessel
walls, in particular in the smooth muscle cells. The
study demonstrates the importance of specific time
points in intracellular signaling, and that activation of
inflammatory cascades at the beginning of incubation
may not affect the inhibitory effect of the MEK1/2 an-
tagonist U0126.
Levels of p-ERK1/2 and p-CaMKII were evaluated by
western blot and immunohistochemistry. Previous stud-
ies have shown that p-CaMKII levels were highest at
0 hours [22] while p-ERK1/2 increased during the organ
culture and peaked between 3 and 6 hours of incubation
[21,30]. This study confirms our hypothesis that addition
of a CaMKII inhibitor at 0 hours, or a MEK1/2 inhibitor
at a time interval between 0 and 6 hours, has a strong
inhibitory effect on the action of these kinases and their
downstream inflammatory-associated targets. Although
p-CaMKII expression was found to be reduced at 6 and
24 hours of incubation by the organ culture itself, treat-
ment with KN93 at 0 hours may prevent any residual
p-CaMKII from activating ERK1/2. It may also be that
p-CaMKII acts on ERK1/2 in a negative feed-back mech-
anism, however these speculations need to be validated in
further studies.
JNK and p38 are often associated with intracellular
signaling related to inflammation. It has been shown that
p-JNK and p-p38 increase in rat cerebral arteries during
organ culture, ischemic stroke (MCAO) and SAH [7].
Here we examined the effects of CaMKII and MEK1/2
inhibitors on the phosphorylation of JNK and p38 induced
by incubating arteries for 24 hours in the presence or ab-
sence of KN93 or U0126. In the present study, KN93 or
U0126 significantly inhibited JNK and p38 activity, which
could be an explanation for the decrease in inflammation
in the vessel wall during organ culture. In support of this
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JNK activation in platelet activating factor (PAF)-induced
proinflammatory response in THP-1 cells [31].
The relation between inflammation and apoptosis and
the role of caspase-3 has been well established in different
cell types [32]. It has been shown that caspase-dependent
MEKK1 cleavage results in JNK activation and apoptosis
[13]. This study demonstrates that KN93 not only has an
inhibitory effect on increased caspase-3 mRNA levels, but
also on p-JNK and p-p38 during organ culture. This
response was more pronounced when KN93 was added
at the start of the incubation. In contrast, the MEK1/2
inhibitor decreased caspase-3 mRNA levels significantly
when administered up to 6 hours after initiating the
incubation. It seems that U0126 has its most potent
effect when given at 6 hours. This is in agreement with
our previous study that evaluated possible cross-talk be-
tween CaMKII and ERK1/2 in the process of endothelin
receptor upregulation during organ culture [22]. We dem-
onstrate here significantly attenuated ERK1/2 activity after
24 hours of organ culture when the CaMKII inhibitor
KN93 was given at 0 or 6 hours, however the ERK1/2
inhibitor U0126 did not affect the CaMKII activity. Taken
together, the previous and present studies suggest that
upstream CaMKII activation results in the activation of
ERK1/2 with subsequent downstream inflammatory and
apoptotic consequences.
TNFR1 has an important role in apoptosis and inflam-
mation within many cell types [33]. TNFRs can be acti-
vated by TNF-α directly [24], by serum starvation in
human colon carcinoma cells [23], or found in human air-
way smooth muscle cells [34] which results in activation
of JNK, p38, and ERK1/2 [34]. Interestingly, our study
showed that U0126 decreased TNFR1 protein expression
indicating that there is cross-talk between ERK1/2 and
TNFR1 signaling. In support of this, a study has reported
that U0126 attenuated TNFR1 expression in cerebral
vessels after organ culture and ischemic stroke [5].
A relation between CaMKII and inflammatory molecules
such as TNF-α, NF-κB [35], and T cell receptors have been
previously reported [36]. Activation of NF-κB receptor
activator or T cell receptor/CD3 leads to the activation of
signaling cascades which includes calcium signaling
and CaMKII [35,36]. The inhibitory effect of KN93 on
TNFR1 suggests a possible cross-talk between CaMKII
and TNFR1 in cerebrovascular inflammation during
organ culture. Interestingly, U0126 and KN93 have in-
hibitory effects both on the upregulation of endothelin
receptors and on inflammation in cerebral VSMCs. The
present study suggests time-dependent involvement of
CaMKII and ERK1/2 in cerebrovascular inflammation
using an in vitro model that mimics ischemic-like vascular
wall changes. Using the same in vitro model, a previous
study of cerebral arteries has shown that TNF-αpotentiates ETB receptor-mediated contraction [37], thus
linking inflammation with cerebrovascular receptor upreg-
ulation. On the other hand, TNF-α and IL-6 themselves
may cause enhanced endothelin-1 production that can
interact with ETA and ETB receptors in VSMCs and
promote vasoconstriction [24]. We propose that there is
involvement of an inflammatory mechanism that affects
endothelin receptor upregulation in cerebral arteries.
Further studies are needed to reveal the molecular rela-
tionship between receptor upregulation and inflamma-
tion, as well as validation of the present observations
using in vivo stroke models, which eventually could un-
cover novel targets for stroke therapy.
Conclusions
This study shows the importance of the timely activation
of ERK1/2 and CaMKII signaling and the effect on
downstream inflammatory-associated kinases and media-
tors. Inhibition of these signals at appropriate time points
may have an important role in reducing cerebrovascular
inflammation, and in turn, cerebral ischemic damage.
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